In studies using an insulin lowering agent, dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduction in insulin levels slowed obesity-accelerated tumor growth of both syngeneic breast and colon cancer models. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.